Pharma major Dr Reddy’s Laboratories Ltd said the new pricing policy might impact 3-4 per cent of its finished dosage sales in the domestic market.

Source

Dr Reddy’s Lab riding high on US generics market growthFourth quarter profit surges 66% to Rs 571 cr;.

Source

Pharma major Dr Reddy’s Laboratories Ltd’s standalone net profit has increased 78. 3 per cent to Rs 378 crore in the fourth quarter ended March 31, 2013, compared with Rs 212 crore in the same period last year.

Source

53 per cent stake in the company at the end of March 2013 quarter. During the last quarter ended March 31, 2013, foreign institutional investors (FIIs) have acquired 5. 93 million shares representing 3. 49 per cent stake in the company, while DIIs sold 2. 95 per cent stake. As on March 31, 2013, promoters hold 25.

Source

Dr Reddy’s Labs withdraws muscle relaxant drug from US market Hyderabad, Apr 11:   Dr Reddy’s Laboratories has initiated recall of its tizanidine tablets, used as a muscle relaxant, from the US market due to labelling issues.

Source

The company has entered into two lease agreements for a 75,500-sq ft office facility and a 31,000 sq ft lab facility with National Business Parks, it said in a filing with the BSE today.

Source

The Reclast brand had a total US sales of about $355 million for the 12 months ended February 2013, according to IMS Health, the Hyderabad-based company said in a release.

Source